ARS Pharmaceuticals, a biopharmaceutical company specializing in allergy treatments, announced it will release its third quarter 2026 financial results on November 5, 2026. The company will hold a conference call and webcast to discuss the results, accessible via registration on their website. ARS Pharma is known for its needle-free epinephrine nasal spray, neffy®, approved for emergency allergy treatment in the U.S., EU, and China. Investors and interested parties can listen to the webcast live or access a replay for 30 days afterward.
ARS Pharmaceuticals' upcoming Q3 2026 financial results provide context for readers. For those following health-sector stocks, here is Pluang's market snapshot as of Oct 29, 2026 02:12 WIB: out of 150 priced US health stocks, 87 advanced and 62 declined. Notable movers include Butterfly Network Inc. Class A Common Stock (BFLY) up 5.15% at USD 7.76 with a typical hold time of 14 days, Alumis Inc. (ALMS) up 5.12% at USD 6.98, and Hims and Hers Health Inc (HIMS) up 4.80% at USD 29.26, with Pluang order activity showing 12% sell and 88% buy, and a typical hold time of 23 days.
SpaceX reported a strong Q3 with revenue up 161% year-over-year to $14.6 billion and a net profit of $4.4 billion, reversing last year's loss. Starlink, its satellite internet service, grew revenue by nearly 70% to $5.2 billion and added 1.6 million ...
SPIE, a leading European multi-technical services provider, has signed an agreement to acquire a 76% stake in SAR ANLAGENBAU GmbH, a major electrical engineering and automation firm based in Austria and Germany. This acquisition will enhance SPIE's p...
SPIE, a European leader in energy and communication services, has agreed to acquire a 76% stake in SAR ANLAGENBAU GmbH, a key electrical engineering and automation firm in Austria and Germany. This acquisition will broaden SPIE's service portfolio in...
The global dermatological therapeutics market is projected to grow from about $43 billion in 2025 to $97 billion by 2034, with a compound annual growth rate of around 10%. This growth is fueled by increasing cases of acne, psoriasis, and other chroni...
Blockchain.com has launched TRX options trading, providing easier access to TRON's native token through its platform. This move expands the TRON ecosystem's reach by simplifying options trading for retail and institutional users worldwide. TRON, know...
